Medications

Trial results of new drug for generalized myasthenia gravis

Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...

Medical research

New report guides drug-device combination risk management

Experts from industry and the U.S. Food and Drug Administration (FDA) recently joined forces to take a closer look at the interface of medical device and drug development, called combination products. Their new technical ...

Diseases, Conditions, Syndromes

NY airports, hospitals under pressure as virus cases mount

The Federal Aviation Administration briefly suspended flights to New York City-area airports on Saturday because of coronavirus-related staffing issues as the number of confirmed cases in New York state soared above 10,000.

page 3 from 9